JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting

Sina Nikayin, Taeho Greg Rhee, Maria Elena Cunningham, Christina A. de Fontnouvelle, Robert Ostroff, Gerard Sanacora, Samuel T. Wilkinson

JAMA Psychiatry May 11, 2022 DOI: 10.1001/jamapsychiatry.2022.1074 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Comparative analysis Peer reviewed
Population	Patients treated with intravenous ketamine or intranasal esketamine in a clinical setting
Interventions	Intravenous ketamine Intranasal esketamine
Topics	Depression Esketamine Ketamine
Keywords	Otorhinolaryngology Neurology Family medicine Depression economics Medline
Citations	43
Key points	Patients treated with intravenous ketamine or intranasal esketamine showed similar trajectories of depression severity.

Abstract

This comparative analysis examines the trajectory of depression severity among patients treated with intravenous ketamine or intranasal esketamine in a clinical setting.